255 related articles for article (PubMed ID: 33916250)
21. Multi-biomarker panel signature as the key to diagnosis of ovarian cancer.
Muinao T; Deka Boruah HP; Pal M
Heliyon; 2019 Dec; 5(12):e02826. PubMed ID: 31867451
[TBL] [Abstract][Full Text] [Related]
22. Current clinical use of biomarkers for epithelial ovarian cancer.
Moore RG; Maclaughlan S
Curr Opin Oncol; 2010 Sep; 22(5):492-7. PubMed ID: 20613519
[TBL] [Abstract][Full Text] [Related]
23. CA125 and Ovarian Cancer: A Comprehensive Review.
Charkhchi P; Cybulski C; Gronwald J; Wong FO; Narod SA; Akbari MR
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322519
[TBL] [Abstract][Full Text] [Related]
24. Molecular Biomarkers for Early Detection and Prevention of Ovarian Cancer-A Gateway for Good Prognosis: A Narrative Review.
Yadav G; Vashisht M; Yadav V; Shyam R
Int J Prev Med; 2020; 11():135. PubMed ID: 33088463
[TBL] [Abstract][Full Text] [Related]
25. Urine Biomarkers for the Early Detection of Ovarian Cancer - Are We There Yet?
Grayson K; Gregory E; Khan G; Guinn BA
Biomark Cancer; 2019; 11():1179299X19830977. PubMed ID: 30833816
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer.
Pal MK; Jaiswar SP; Dwivedi VN; Tripathi AK; Dwivedi A; Sankhwar P
Cancer Biol Med; 2015 Dec; 12(4):328-41. PubMed ID: 26779370
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers for early detection of ovarian cancer.
Nguyen L; Cardenas-Goicoechea SJ; Gordon P; Curtin C; Momeni M; Chuang L; Fishman D
Womens Health (Lond); 2013 Mar; 9(2):171-85; quiz 186-7. PubMed ID: 23477323
[TBL] [Abstract][Full Text] [Related]
28. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
29. microRNA and Ovarian Cancer.
Langhe R
Adv Exp Med Biol; 2015; 889():119-51. PubMed ID: 26659000
[TBL] [Abstract][Full Text] [Related]
30. Glycomic analysis of membrane glycoproteins with bisecting glycosylation from ovarian cancer tissues reveals novel structures and functions.
Allam H; Aoki K; Benigno BB; McDonald JF; Mackintosh SG; Tiemeyer M; Abbott KL
J Proteome Res; 2015 Jan; 14(1):434-46. PubMed ID: 25437919
[TBL] [Abstract][Full Text] [Related]
31. A review of co-registered transvaginal photoacoustic and ultrasound imaging for ovarian cancer diagnosis.
Zhu Q
Curr Opin Biomed Eng; 2022 Jun; 22():. PubMed ID: 36148033
[TBL] [Abstract][Full Text] [Related]
32. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.
El Bairi K; Kandhro AH; Gouri A; Mahfoud W; Louanjli N; Saadani B; Afqir S; Amrani M
Cell Oncol (Dordr); 2017 Apr; 40(2):105-118. PubMed ID: 27981507
[TBL] [Abstract][Full Text] [Related]
33. Ovarian Cancer: Biomarkers and Targeted Therapy.
Radu MR; Prădatu A; Duică F; Micu R; Creţoiu SM; Suciu N; Creţoiu D; Varlas VN; Rădoi VE
Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34207450
[TBL] [Abstract][Full Text] [Related]
34. Reasons for diagnostic delay in gynecological malignancies.
Vandborg MP; Christensen RD; Kragstrup J; Edwards K; Vedsted P; Hansen DG; Mogensen O
Int J Gynecol Cancer; 2011 Aug; 21(6):967-74. PubMed ID: 21792008
[TBL] [Abstract][Full Text] [Related]
35. Advances of exosome in the development of ovarian cancer and its diagnostic and therapeutic prospect.
Shen J; Zhu X; Fei J; Shi P; Yu S; Zhou J
Onco Targets Ther; 2018; 11():2831-2841. PubMed ID: 29844681
[TBL] [Abstract][Full Text] [Related]
36. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
[TBL] [Abstract][Full Text] [Related]
37. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
38. Gynecological cancers: A summary of published Indian data.
Maheshwari A; Kumar N; Mahantshetty U
South Asian J Cancer; 2016; 5(3):112-20. PubMed ID: 27606294
[TBL] [Abstract][Full Text] [Related]
39. Multiple biomarker panels for early detection of ovarian cancer.
Yurkovetsky ZR; Linkov FY; E Malehorn D; Lokshin AE
Future Oncol; 2006 Dec; 2(6):733-41. PubMed ID: 17155900
[TBL] [Abstract][Full Text] [Related]
40. Recognizing Gynecological Cancer in Primary Care: Risk Factors, Red Flags, and Referrals.
Funston G; O'Flynn H; Ryan NAJ; Hamilton W; Crosbie EJ
Adv Ther; 2018 Apr; 35(4):577-589. PubMed ID: 29516408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
